Bococizumab

Names

[ Name ]:
Bococizumab

Biological Activity

[Description]:

Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease

Research Areas >> Cardiovascular Disease

Research Areas >> Metabolic Disease

[Target]

PCSK9[1]

[In Vivo]

Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2]. Animal Model: Pregnant Sprague-Dawley (SD) rats[1] Dosage: 0, 10, 30, and 100 mg/kg Administration: Intravenous injection (i.v.) Result: Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.

[References]

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505.

[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.